Jerry Berg, NP
Family · Ashtabula, OHNPI 1467900951
Payments from drug & device makers
Across 1,084 payments — averaging $31.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$16K
- Nestle Healthcare Nutrition Inc.$6K
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Ardelyx, Inc.$1K
- Johnson & Johnson$1K
- plus $5K from 26 others
What the payments were for
- Consulting fees$2,6008%
- Speaking & faculty fees$14,49542%
- Travel & lodging$3,48410%
- Food & beverage$13,54439%
- Education$1831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aimmune Therapeutics, Inc. | 73 | $15,903 |
| Nestle Healthcare Nutrition Inc. | 81 | $6,332 |
| AbbVie | 238 | $2,935 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 221 | $2,394 |
| Ardelyx, Inc. | 97 | $1,152 |
| Johnson & Johnson(2 entities) | 66 | $1,056 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $621 |
| QOL Medical, LLC | 42 | $487 |
| Sanofi | 33 | $451 |
| Regeneron Healthcare Solutions, Inc. | 28 | $383 |
| Vivus LLC | 24 | $380 |
| Merck | 19 | $350 |
| Pfizer | 18 | $273 |
| Redhill Biopharma Inc. | 21 | $224 |
| Ironwood Pharmaceuticals, Inc | 12 | $209 |
| Phathom Pharmaceuticals, Inc. | 11 | $166 |
| Daiichi Sankyo Inc. | 8 | $130 |
| Madrigal Pharmaceuticals | 5 | $125 |
| Ferring Pharmaceuticals Inc. | 8 | $123 |
| Gilead | 8 | $117 |
| Braintree Laboratories, Inc. | 7 | $105 |
| Digestive Care, Inc. | 5 | $89 |
| Ipsen Biopharmaceuticals, Inc | 3 | $68 |
| Boehringer Ingelheim | 3 | $48 |
| Biocon Biologics Inc | 2 | $41 |
| Organon | 2 | $33 |
| Intercept Pharmaceuticals, Inc. | 2 | $29 |
| Bristol Myers Squibb | 2 | $25 |
| Fresenius Kabi USA, LLC | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Celltrion USA Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,306 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 173 | $724,115 |
| CreonLipase/Protease/Amylase | 109 | $454,645 |
| XifaxanRifaximin | 45 | $148,944 |
| LinzessLinaclotide | 137 | $118,575 |
| IbsrelaTenapanor Hcl | 51 | $91,142 |
| VoqueznaVonoprazan Fumarate | 23 | $16,363 |
| MotegrityPrucalopride Succinate | 24 | $13,604 |
| Ondansetron Hcl | 77 | $10,920 |
| Mesalamine | 25 | $10,831 |
| Lubiprostone | 53 | $10,229 |
| Dexlansoprazole DrDexlansoprazole | 40 | $7,178 |
| Omeprazole | 466 | $5,860 |
| MovantikNaloxegol Oxalate | 12 | $4,934 |
| Pantoprazole Sodium | 499 | $4,851 |
| Sucralfate | 115 | $4,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $15,903 | $724,115173 claims |
| AbbVieCreon, Linzess | $2,935 | $573,220246 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $2,394 | $151,04460 claims |
| Ardelyx, Inc.Ibsrela | $1,152 | $91,14251 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $166 | $16,36323 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $621 | $13,60424 claims |
| Redhill Biopharma Inc.Movantik | $224 | $4,93412 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $123 | $3,96923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Ashtabula
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.